RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+7.38%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1.47B
AUM Growth
+$1.47B
(+2.7%)
Cap. Flow
-$25.1M
Cap. Flow
% of AUM
-1.7%
Top 10 Holdings %
Top 10 Hldgs %
26.19%
Holding
101
New
9
Increased
29
Reduced
33
Closed
7
Top Buys
| 1 |
Biogen
BIIB
|
$24.4M |
| 2 |
Veeva Systems
VEEV
|
$19.9M |
| 3 |
Pfizer
PFE
|
$19.6M |
| 4 |
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
|
$13.1M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$12.3M |
Top Sells
| 1 |
Johnson & Johnson
JNJ
|
$41.2M |
| 2 |
Bristol-Myers Squibb
BMY
|
$13.4M |
| 3 |
NovoCure
NVCR
|
$13.3M |
| 4 |
LivaNova
LIVN
|
$12.2M |
| 5 |
Eli Lilly
LLY
|
$11.8M |
Sector Composition
| 1 | Healthcare | 94.98% |
| 2 | Industrials | 1.94% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
UnitedHealth
UNH
$281B
| $50.1M | 3.4% | 125,000 +12,000 | +11% | +$4.81M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $49.2M | 3.34% | 525,000 -70,000 | -12% | -$6.55M |
|
3
Vertex Pharmaceuticals
VRTX
$100B
| $43.5M | 2.95% | 215,897 +47,476 | +28% | +$9.57M |
|
4
Jazz Pharmaceuticals
JAZZ
$7.75B
| $39.1M | 2.65% | 220,000 -30,000 | -12% | -$5.33M |
|
5
Elevance Health
ELV
$71.8B
| $36.3M | 2.46% | 95,000 | – | – |
|
6
AbbVie
ABBV
$372B
| $36M | 2.45% | 320,000 -48,000 | -13% | -$5.41M |
|
7
Teladoc Health
TDOC
$1.37B
| $34.9M | 2.37% | 210,000 +20,000 | +11% | +$3.33M |
|
8
Medtronic
MDT
$119B
| $33.9M | 2.3% | 273,000 -62,000 | -19% | -$7.7M |
|
9
CVS Health
CVS
$92.8B
| $31.7M | 2.15% | 380,000 -70,000 | -16% | -$5.84M |
|
|
10
Biogen
BIIB
$19.4B
| $31.2M | 2.12% | 90,000 +70,500 | +362% | +$24.4M |
|
11
Cigna
CI
$80.3B
| $30.9M | 2.1% | 130,500 +20,500 | +19% | +$4.86M |
|
12
Abbott
ABT
$231B
| $29M | 1.97% | 250,000 -25,000 | -9% | -$2.9M |
|
|
13
Eli Lilly
LLY
$657B
| $27.3M | 1.85% | 118,800 -51,200 | -30% | -$11.8M |
|
|
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $26.7M | 1.81% | 165,000 +15,000 | +10% | +$2.42M |
|
|
15
NovoCure
NVCR
$1.38B
| $26.6M | 1.81% | 120,000 -60,000 | -33% | -$13.3M |
|
16
Thermo Fisher Scientific
TMO
$186B
| $25.2M | 1.71% | 50,000 +5,000 | +11% | +$2.52M |
|
|
XLRN
17
DELISTED
Acceleron Pharma Inc.
XLRN
| $25.1M | 1.7% | 200,000 +40,000 | +25% | +$5.02M |
|
|
SGEN
18
DELISTED
Seagen Inc. Common Stock
SGEN
| $24.9M | 1.69% | 157,925 +77,925 | +97% | +$12.3M |
|
19
Humana
HUM
$36.5B
| $24.4M | 1.65% | 55,000 -14,000 | -20% | -$6.2M |
|
|
AXNX
20
DELISTED
Axonics, Inc. Common Stock
AXNX
| $24.1M | 1.64% | 380,000 -30,000 | -7% | -$1.9M |
|
21
Merck
MRK
$210B
| $23.3M | 1.58% | 300,000 +30,000 | +11% | +$2.33M |
|
|
22
Veeva Systems
VEEV
$44B
| $23.3M | 1.58% | 75,000 +64,000 | +582% | +$19.9M |
|
23
Alnylam Pharmaceuticals
ALNY
$58.5B
| $22.9M | 1.55% | 135,000 | – | – |
|
24
Zimmer Biomet
ZBH
$21B
| $22.5M | 1.53% | 140,000 +10,000 | +8% | +$1.61M |
|
25
Boston Scientific
BSX
$156B
| $22.2M | 1.51% | 520,000 -150,000 | -22% | -$6.41M |
|